Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial
J Argente, CF Verge, U Okorie, I Fennoy… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, has been shown to
reduce hunger and weight in patients aged 6 years and older with proopiomelanocortin …
reduce hunger and weight in patients aged 6 years and older with proopiomelanocortin …
[HTML][HTML] A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide …
J Jiang, M Shi, S Wu, M Cao - Journal of Clinical and …, 2024 - pmc.ncbi.nlm.nih.gov
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
receptor agonists are increasingly used in the management of type 2 diabetes mellitus and …
receptor agonists are increasingly used in the management of type 2 diabetes mellitus and …
Monogenic Obesity in Children: Current Perspectives and Clinical Implications
CCC Lopes, VOM Azzini, NS Beker, EB Lopes… - International Journal of …, 2024 - ijmscr.org
Introduction: Monogenic obesity is characterized by a mutation in a single gene, which
directly influences metabolism, appetite control or other biological pathways associated with …
directly influences metabolism, appetite control or other biological pathways associated with …